"[R]ebates are not only driving higher list prices -- they are driving higher net prices and overall drug benefit costs.... We need to adopt a system that is focused on getting the right patient, the right drug, in the right dose and amount, at the right time, in the right location, and at the best price (considering what it truly costs to do everything else). This is a system that is driven by the value to the patient and not to the PBM."  MORE >>